Achievement of Proteinuria Targets ≤0.4 g/g in Lupus Nephritis: A Post Hoc Analysis of the AURORA 1 Study of Voclosporin (UKKW 2026) - Mar 16, 2026 - Abstract #417; Pres time: Mar 12, 2026; 02:00 PM - 03:30 PM; Location: QUEENS SUITE 2; "The 52-week, Phase 3 AURORA 1 study showed that the addition of voclosporin to low-dose glucocorticoids and mycophenolate mofetil (MMF) led to significantly greater and earlier reductions in proteinuria compared to treatment with low-dose glucocorticoids and MMF alone...Participants received voclosporin (23.7 mg) or placebo twice daily, plus MMF (2 g/day) and low-dose glucocorticoids (intravenous methylprednisolone on Days 1 and 2 [total 1 g], followed by oral prednisone at a starting dose of 20–25 mg/day, tapered to ≤2.5 mg/day by Week 16)... Nearly half (49.0%) of participants in AURORA 1 achieved a UPCR ≤0.4 g/g at least once during the 52- week study. In the voclosporin group, 109 (60.9%) achieved UPCR ≤0.4 g/g. In the control group, 66 (37.1%) participants achieved a UPCR ≤0.4 g/g (mean [SD] minimum, 0.18 [0.098] g/g)."
Retrospective data • Chronic Kidney Disease • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease
|
|
Professor of Medicine and Director of Nephrology Rovin Brad H. 2; Associate Professor of Medicine and Nephrologist Almaani Salem2; Senior Director, Clinical Development Hodge Lucy 3; Director, Clinical Operations Birardi Vanessa3; Sadiq Ahmed, Executive Director, Medical Affairs Yap Ernie3
|